Data Year:

For its 2025 fiscal year, HIMS & HERS HEALTH INC, listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2025
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
Melissa Baird
Former Chief Operating Officer
Total Compensation $8,392,871 View details Pay Rank By Title In Biotechnology industry #8 View more
Andrew Dudum
Chief Executive Officer and Chairman
Total Compensation $22,958,907 View details Pay Rank By Title In Biotechnology industry #22 View more
Soleil Boughton
Chief Legal Officer
Total Compensation $4,796,709 View details Pay Rank By Title In Biotechnology industry #3 View more
Mike Chi
Chief Operating Officer (previously Chief Commercial Officer)
Total Compensation $7,727,713 View details Pay Rank By Title In Biotechnology industry #10 View more
Yemi Okupe
Chief Financial Officer
Total Compensation $8,398,808 View details Pay Rank By Title In Biotechnology industry #17 View more
Mohamed Elshenawy
Chief Technology Officer
Total Compensation $60,869,746 View details Pay Rank By Title In Biotechnology industry #1 View more
Nader Kabbani
Former Chief Operating Officer
Total Compensation $14,862,305 View details Pay Rank By Title In Biotechnology industry #1 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at HIMS & HERS HEALTH INC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. HIMS & HERS HEALTH INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. HIMS & HERS HEALTH INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Melissa Baird
Former Chief Operating Officer
Total Cash $341,292 Equity $8,048,579 Other $3,000 $8,392,871
Andrew Dudum
Chief Executive Officer and Chairman
Total Cash $1,080,555 Equity $21,635,352 Other $243,000 $22,958,907
Soleil Boughton
Chief Legal Officer
Total Cash $769,440 Equity $4,024,269 Other $3,000 $4,796,709
Mike Chi
Chief Operating Officer (previously Chief Commercial Officer)
Total Cash $825,914 Equity $6,898,799 Other $3,000 $7,727,713
Yemi Okupe
Chief Financial Officer
Total Cash $907,638 Equity $7,473,689 Other $17,481 $8,398,808
Mohamed Elshenawy
Chief Technology Officer
Total Cash $3,653,470 Equity $57,216,276 Other $0 $60,869,746
Nader Kabbani
Former Chief Operating Officer
Total Cash $1,227,273 Equity $13,486,199 Other $148,833 $14,862,305
For its 2025 fiscal year, HIMS & HERS HEALTH INC, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Andrew Dudum CEO Pay $22,958,907 Median Employee Pay $84,402 CEO Pay Ratio 272:1
For its 2025 fiscal year, HIMS & HERS HEALTH INC, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Andrea Perez Total Cash $241,931
Anja Manuel Total Cash $240,931
Christiane Pendarvis Total Cash $236,931
Christopher Payne Total Cash $246,079
David Wells Total Cash $274,579
Deb Autor Total Cash $305,931
Delos Cosgrove, M.D. Total Cash $226,931
Kåre Schultz Total Cash $230,931
Patrick Carroll, M.D. Total Cash $226,931
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.